Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 337

1.

Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.

Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, Fassas A, van Rhee F, Klaus H, Barlogie B, Anaissie EJ.

Bone Marrow Transplant. 2006 Oct;38(7):501-6.

PMID:
16980998
[PubMed - indexed for MEDLINE]
2.

Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.

Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vokurka S, Quinn B, McCann S; European Blood and Marrow Transplantation Mucositis Advisory Group.

J Clin Oncol. 2008 Mar 20;26(9):1519-25. doi: 10.1200/JCO.2007.13.6028. Epub 2008 Feb 11.

PMID:
18268357
[PubMed - indexed for MEDLINE]
3.

Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.

Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S.

J Support Oncol. 2007 May;5(5):231-5.

PMID:
17564153
[PubMed - indexed for MEDLINE]
4.

Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.

Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ; Spanish Myeloma Group/PETHEMA.

Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54.

PMID:
18022574
[PubMed - indexed for MEDLINE]
5.

Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.

Vokurka S, Steinerova K, Karas M, Koza V.

Bone Marrow Transplant. 2009 Nov;44(9):601-5. doi: 10.1038/bmt.2009.66. Epub 2009 Apr 6.

PMID:
19349956
[PubMed - indexed for MEDLINE]
6.

Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.

Novitzky N, Thomson J, Thomas V, du Toit C, Mohamed Z, McDonald A.

Biol Blood Marrow Transplant. 2010 Oct;16(10):1402-10. doi: 10.1016/j.bbmt.2010.04.002. Epub 2010 Apr 10.

PMID:
20385248
[PubMed - indexed for MEDLINE]
7.

Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.

Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R, Barlogie B.

Clin Cancer Res. 1996 Jun;2(6):947-52.

PMID:
9816255
[PubMed - indexed for MEDLINE]
Free Article
8.

A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.

Abidi MH, Agarwal R, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Ratanatharathorn V, Zonder J, Uberti J.

Biol Blood Marrow Transplant. 2013 Jan;19(1):56-61. doi: 10.1016/j.bbmt.2012.08.003. Epub 2012 Aug 11.

PMID:
22892551
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.

Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR, Ansell SM.

Br J Haematol. 2008 Oct;143(2):268-73. doi: 10.1111/j.1365-2141.2008.07342.x. Epub 2008 Aug 10.

PMID:
18699848
[PubMed - indexed for MEDLINE]
10.

The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.

McCann S, Schwenkglenks M, Bacon P, Einsele H, D'Addio A, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vorkurka S, Quinn B, Blijlevens N; EBMT Mucositis Advisory Group.

Bone Marrow Transplant. 2009 Jan;43(2):141-7. doi: 10.1038/bmt.2008.299. Epub 2008 Sep 8.

PMID:
18776926
[PubMed - indexed for MEDLINE]
11.

Use of sidestream dark-field (SDF) imaging for assessing the effects of high-dose melphalan and autologous stem cell transplantation on oral mucosal microcirculation in myeloma patients.

Milstein DM, te Boome LC, Cheung YW, Lindeboom JA, van den Akker HP, Biemond BJ, Ince C.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Jan;109(1):91-7. doi: 10.1016/j.tripleo.2009.08.041.

PMID:
20123381
[PubMed - indexed for MEDLINE]
12.

Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.

Blanes M, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A, Bladé J, San Miguel JF, Sanz MA, de la Rubia J.

Biol Blood Marrow Transplant. 2013 Jan;19(1):69-74. doi: 10.1016/j.bbmt.2012.08.009. Epub 2012 Aug 13.

PMID:
22897964
[PubMed - indexed for MEDLINE]
13.

Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.

Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB.

Biol Blood Marrow Transplant. 1999;5(5):306-15.

PMID:
10534061
[PubMed - indexed for MEDLINE]
14.

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.

Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31. Epub 2007 May 29.

PMID:
17640596
[PubMed - indexed for MEDLINE]
15.

Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue.

Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R, Fraser CJ, Scarffe JH.

Br J Haematol. 2000 Aug;110(2):292-9.

PMID:
10971384
[PubMed - indexed for MEDLINE]
16.

The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.

Vokurka S, Bystricka E, Scudlova J, Mazur E, Visokaiova M, Vasilieva E, Brandejsova R, Chvojkova I, Vrabcova M, Vitkova J, Mjartanova D, Vodickova M, Bockova J, Streinerova K.

Eur J Oncol Nurs. 2011 Dec;15(5):508-12. doi: 10.1016/j.ejon.2011.01.006. Epub 2011 Feb 10.

PMID:
21310656
[PubMed - indexed for MEDLINE]
17.

Factors influencing the incidence and severity of oral mucositis in patients undergoing autologous stem cell transplantation.

Salvador PT.

Can Oncol Nurs J. 2005 Winter;15(1):29-34. English, French.

PMID:
15779780
[PubMed - indexed for MEDLINE]
18.

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.

Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, Joske D, Grigg A, McKendrick J, Prosser I, Lowenthal R, Deveridge S, Taylor K; Australasian Leukemia and Lymphoma Group.

Bone Marrow Transplant. 2005 May;35(10):971-7.

PMID:
15778725
[PubMed - indexed for MEDLINE]
19.

Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial.

Abidi MH, Agarwal R, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Zonder J, Ratanatharathorn V, Uberti J.

Biol Blood Marrow Transplant. 2012 Sep;18(9):1455-61. doi: 10.1016/j.bbmt.2012.03.010. Epub 2012 Mar 24.

PMID:
22453252
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Long-term outcome of autologous stem cell transplantation in light chain deposition disease.

Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.

Nephrol Dial Transplant. 2008 Jun;23(6):2052-7. doi: 10.1093/ndt/gfm918. Epub 2008 Jan 4.

PMID:
18178602
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk